Cargando…

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing

Detalles Bibliográficos
Autores principales:	Suwa, Michihiro, Nohara, Yuki, Morii, Isao, Kino, Masaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483109/ https://www.ncbi.nlm.nih.gov/pubmed/37693231 http://dx.doi.org/10.1253/circrep.CR-66-0012

Ejemplares similares

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry
por: Kim, Ju Youn, et al.
Publicado: (2022)

High incidence of major bleeding with off-label use of edoxaban
por: Fukui, Rika, et al.
Publicado: (2021)

Corrigendum to “Rheumatological Findings in Candidates for Valvular Heart Surgery”
por: Owlia, Mohammad Bagher, et al.
Publicado: (2017)

Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies
por: Chan, Yi-Hsin, et al.
Publicado: (2023)

Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Corrigendum to: Family-joining: A fast distance-based method for constructing generally labeled trees
por: Kalaghatgi, Prabhav, et al.
Publicado: (2020)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
por: Singkham, Noppaket, et al.
Publicado: (2022)

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations [Corrigendum]
Publicado: (2019)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Corrigendum to “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial”
por: Watanabe, K., et al.
Publicado: (2016)

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
por: Ikeda, Takanori, et al.
Publicado: (2019)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015)

Corrigendum to “Benefits of Low-Dose CT Scan of Head for Patients with Intracranial Hemorrhage”
Publicado: (2021)

Corrigendum to “Effects of Shenfu Injection in the Treatment of Septic Shock Patients: A Multicenter, Controlled, Randomized, Open-Label Trial”
por: Li, Yi, et al.
Publicado: (2016)

Radiolabeling and Preliminary Evaluation of (99m)Tc-Labeled DNA Cube Nanoparticles as Potential Tracers for SPECT Imaging [Corrigendum]
Publicado: (2022)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
Publicado: (2022)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Corrigendum to “Improvement of Memory by Means of Ultra-Low Doses of Antibodies to S-100B Antigen”
por: Evidence-Based Complementary and Alternative Medicine,
Publicado: (2020)

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial – CORRIGENDUM
por: Dai, Minhan, et al.
Publicado: (2021)

Corrigendum to “High Dose Dexmedetomidine: Effective as a Sole Agent Sedation for Children Undergoing MRI”
por: Ahmed, Sheikh Sohail, et al.
Publicado: (2015)

Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema [Corrigendum]
Publicado: (2016)

Corrigendum to “Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction”
por: Ahmad, Ijaz, et al.
Publicado: (2017)

Increased radiosensitivity of colorectal tumors with intra-tumoral injection of low dose of gold nanoparticles [Corrigendum]
Publicado: (2019)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

A Prospective, Open-Label Study to Evaluate the Impact of VYC-12L Injection on Skin Quality Attributes in Healthy Volunteers [Corrigendum]
Publicado: (2022)

Corrigendum: The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
Publicado: (2021)

Preparation of AS1411 Aptamer Modified Mn-MoS(2) QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma [Corrigendum]
Publicado: (2023)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Corrigendum: High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
Publicado: (2022)

Corrigendum to “Total Intravenous Anaesthesia with High-Dose Remifentanil Does Not Aggravate Postoperative Nausea and Vomiting and Pain, Compared with Low-Dose Remifentanil: A Double-Blind and Randomized Trial”
por: Kim, Seong-Hyop, et al.
Publicado: (2019)

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
por: Briasoulis, Alexandros, et al.
Publicado: (2020)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Multiple drugs interaction: Off-label use and increased plasma concentration of rivaroxaban: case report
Publicado: (2021)

Corrigendum to “Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV”
por: Li, Fengjiao, et al.
Publicado: (2020)

Corrigendum to “Benign course after acute high dose levothyroxine intoxication in a 3-year-old boy”
por: Hartman, Stan, et al.
Publicado: (2020)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mijr8hto618c96s5vftbdlme66